Fluvastatin in the Treatment of Dyslipidemia Associated with Chronic Kidney Failure and Renal Transplantation

REFERENCES

• Jones, C A.; McQuillan, G M.; Kusek, J W.; Eberhardt, M S.; Herman, W H.; Coresh, J.; Salive, M.; Jones, C P.; Agodoa, L Y. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 1998, 32 (6), 992–999. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ojo, A O.; Hanson, J A.; Wolfe, R A.; Leichtman, A B.; Agodoa, L Y.; Port, F K. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000, 57 (1), 307–313. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• van Dijk, P C.; Jager, K J.; de Charro, F.; Collart, F.; Cornet, R.; Dekker, F W.; Gronhagen-Riska, C.; Kramar, R.; Leivestad, T.; Simpon, K.; Briggs, J D. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol. Dial. Transplant. 2001, 16 (6), 1120–1129. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Arend, S M.; Mallat, M J.; Westendorp, R J.; van der Woude, F J.; van Es, L A. Patient survival after renal transplantation; more than 25 years follow-up. Nephrol. Dial. Transplant. 1997, 12 (8), 1672–1679. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Kasiske, B.; Cosio, F G.; Beto, J.; Bolton, K.; Chavers, B M.; Grimm, R. Jr.; Levin, A.; Masri, B.; Parekh, R.; Wanner, C.; Wheeler, D C.; Wilson, P W. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the managing dyslipidemias in chronic kidney disease work group of the national kidney foundation kidney disease outcomes quality initiative. Am. J. Transplant. 2004, 4 (Suppl 7), 13–53. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am. J. Kidney Dis. 2003, 41 (4 Suppl 3), pp. I–IV, S1–91.
   Google Scholar
• Attman, P O.; Alaupovic, P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis. Nephron 1991, 57 (4), 401–410. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Grutzmacher, P.; Marz, W.; Peschke, B.; Gross, W.; Schoeppe, W. Lipoproteins and apolipoproteins during the progression of chronic renal disease. Nephron 1988, 50 (2), 103–111. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Attman, P O.; Samuelsson, O.; Alaupovic, P. Lipoprotein metabolism and renal failure. Am. J. Kidney Dis. 1993, 21 (6), 573–592. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ma, K W.; Greene, E L.; Raij, L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am. J. Kidney Dis. 1992, 19 (6), 505–513. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Keane, W F.; Kasiske, B L.; O'Donnell, M P. Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am. J. Nephrol. 1988, 8 (4), 261–271. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Quaschning, T.; Krane, V.; Metzger, T.; Wanner, C. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am. J. Kidney Dis. 2001, 38 (4 Suppl 1), S14–S19. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• First, M R. Long-term complications after transplantation. Am. J. Kidney Dis. 1993, 22 (3), 477–486. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Vathsala, A.; Weinberg, R B.; Schoenberg, L.; Grevel, J.; Goldstein, R A.; Van Buren, C T.; Lewis, R M.; Kahan, B D. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1989, 48 (1), 37–43. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Hilbrands, L B.; Demacker, P N.; Hoitsma, A J.; Stalenhoef, A F.; Koene, R A. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J. Am. Soc. Nephrol. 1995, 5 (12), 2073–2081. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Aakhus, S.; Dahl, K.; Wideroe, T E. Hyperlipidemia in renal transplant patients. J. Intern. Med. 1996, 239 (5), 407–415. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Segoloni, G P.; Triolo, G.; Cassader, M.; Turello, E.; Ruiu, G.; Messina, M.; Pagano, G F.; Vercellone, A. Dyslipidemia in renal transplantation: a 3-year follow-up. Transplant. Proc. 1993, 25 (3), 2178–2179. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Hilbrands, L B.; Demacker, P N.; Hoitsma, A J. Cyclosporin and serum lipids in renal transplant recipients. Lancet 1993, 341 (8847), 765–766, author reply 7. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Brown, J H.; Anwar, N.; Short, C D.; Bhatnager, D.; Mackness, M I.; Hunt, L P.; Durrington, P N. Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol. Dial. Transplant. 1993, 8 (9), 863–867. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Kasiske, B L. Hyperlipidemia in patients with chronic renal disease. Am. J. Kidney Dis. 1998, 32 (5 Suppl 3), S142–S156. [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Ghanem, H.; van den Dorpel, M A.; Weimar, W.; Man in, T V.A.J.; El-Kannishy, M H.; Jansen, H. Increased low density lipoprotein oxidation in stable kidney transplant recipients. Kidney Int. 1996, 49 (2), 488–493. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Sutherland, W H.; Walker, R J.; Ball, M J.; Stapley, S A.; Robertson, M C. Oxidation of low density lipoproteins from patients with renal failure or renal transplants. Kidney Int. 1995, 48 (1), 227–236. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Apanay, D C.; Neylan, J F.; Ragab, M S.; Sgoutas, D S. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation 1994, 58 (6), 663–669. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Dasgupta, A.; Powell, D.; Saldana, S.; Doria, L. Elevated lipid peroxidation products and depleted transferrin levels in the plasma of kidney transplant recipients. Life Sci. 1990, 46 (1), 67–72. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Jung, K.; Scheifler, A.; Blank, W.; Scholz, D.; Schulze, B D.; Hansen, C. Changed composition of high-density lipoprotein subclasses HDL2 and HDL3 after renal transplantation. Transplantation 1988, 46 (3), 407–409. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Kasiske, B L.; Umen, A J. Persistent hyperlipidemia in renal transplant patients. Medicine (Baltimore) 1987, 66 (4), 309–316.
   PubMed Web of Science ®Google Scholar
• Rao, V K. Posttransplant medical complications. Surg. Clin. North Am. 1998, 78 (1), 113–132. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Cattran, D C.; Steiner, G.; Wilson, D R.; Fenton, S A. Hyperlipidemia after renal transplantation: natural history and pathophysiology. Annu. Intern. Med. 1979, 91 (4), 554–559.
   PubMedGoogle Scholar
• Ponticelli, C.; Barbi, G L.; Cantaluppi, A.; De Vecchi, A.; Annoni, G.; Donati, C.; Cecchettin, M. Lipid disorders in renal transplant recipients. Nephron 1978, 20 (4), 189–195. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Lowry, R P.; Soltys, G.; Peters, L.; Mangel, R.; Sniderman, A D. Type II hyperlipoproteinemia, hyperapobetalipoproteinemia, and hyperalphalipoproteinemia following renal transplantation: implications for atherogenic risk. Transplant. Proc. 1987, 19 (4), 3426–3430. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Raine, A E.; Carter, R.; Mann, J I.; Morris, P J. Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrol. Dial. Transplant. 1988, 3 (4), 458–463. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Schorn, T F.; Kliem, V.; Bojanovski, M.; Bojanovski, D.; Repp, H.; Bunzendahl, H.; Frei, U. Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients. Transpl. Int. 1991, 4 (2), 92–95. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Ballantyne, C M.; Podet, E J.; Patsch, W P.; , et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989, 262 (1), 53–56. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Dorpel, vandenM A.; Ghanem, H.; Rischen-Vos, J.; Veld, Manin'tA J.; Jansen, H.; Weimar, W. Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients]. Kidney Int. 1997, 51 (5), 1608–1612. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Johnson, C.; Ahsan, N.; Gonwa, T.; Holloran, P.; Stegall, M.; Hardy, M.; Metzger, R.; Shield, C. 3rd; Rocher, L.; Scandling, J.; Sorensen, J.; Mulloy, L.; Light, J.; Corwin, C.; Danovitch, G.; Wachs, M.; van Veldhuisen, P.; Salm, K.; Tolzman, D.; Fitzsimmons, W E. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000, 69 (5), 834–841. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Satterthwaite, R.; Aswad, S.; Sunga, V.; Shidban, H.; Bogaard, T.; Asai, P.; Khetan, U.; Akra, I.; Mendez, R G.; Mendez, R. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation 1998, 65 (3), 446–449. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Pirsch, J D.; Miller, J.; Deierhoi, M H.; Vincenti, F.; Filo, R S. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 kidney transplant study group. Transplantation 1997, 63 (7), 977–983. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Groth, C G.; Backman, L.; Morales, J M.; Calne, R.; Kreis, H.; Lang, P.; Touraine, J L.; Claesson, K.; Campistol, J M.; Durand, D.; Wrammer, L.; Brattstrom, C.; Charpentier, B. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European renal transplant study group. Transplantation 1999, 67 (7), 1036–1042. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Moore, R.; Hernandez, D.; Valantine, H. Calcineurin inhibitors and post-transplant hyperlipidemias. Drug Safety 2001, 24 (10), 755–766. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Kasiske, B L. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am. J. Med. 1988, 84 (6), 985–992. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Kasiske, B L.; Guijarro, C.; Massy, Z A.; Wiederkehr, M R.; Ma, J Z. Cardiovascular disease after renal transplantation. J. Am. Soc. Nephrol. 1996, 7 (1), 158–165. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Aakhus, S.; Dahl, K.; Wideroe, T E. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol. Dial. Transplant. 1999, 14 (3), 648–654. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Dimeny, E.; Wahlberg, J.; Lithell, H.; Fellstrom, B. Hyperlipidemia in renal transplantation-risk factor for long-term graft outcome. Eur. J. Clin. Investig. 1995, 25 (8), 574–583. [CSA]
   PubMedGoogle Scholar
• Dimeny, E.; Fellstrom, B.; Larsson, E.; Walhberg, J.; Lithell, H. The role of lipoprotein abnormalities in chronic vascular rejection after kidney transplantation. Transplant. Proc. 1995, 27 (3), 2036–2039., [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Isoniemi, H.; Nurminen, M.; Tikkanen, M J.; von Willebrand, E.; Krogerus, L.; Ahonen, J.; Eklund, B.; Hockerstedt, K.; Salmela, K.; Hayry, P. Risk factors predicting chronic rejection of renal allografts. Transplantation 1994, 57 (1), 68–72. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Fischer, V.; Johanson, L.; Heitz, F.; Tullman, R.; Graham, E.; Baldeck, J.-P.; Robinson, W T. The 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab. Dispos. 1999, 27 (3), 410–416. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Corsini, A.; Bellosta, S.; Baetta, R.; Fumagalli, R.; Paoletti, R.; Bernini, F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 1999, 84 (3), 413–428. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Sabia, H.; Prasad, P.; Smith, H T.; Stoltz, R R.; Rothenberg, P. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. J. Cardiovasc. Pharmacol. 2001, 37 (5), 502–511. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Appel-Dingemanse, S.; Smith, T.; Merz, M. Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome. J. Clin. Pharmacol. 2002, 42 (3), 312–318. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Bellosta, S.; Paoletti, R.; Corsini, A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004, 109 (23 Suppl 1), III50–III57. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Kyrklund, C.; Backman, J T.; Kivisto, K T.; Neuvonen, M.; Laitila, J.; Neuvonen, P J. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther. 2001, 69 (5), 340–345. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Backman, J T.; Kyrklund, C.; Neuvonen, M.; Neuvonen, P J. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 2002, 72 (6), 685–691. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kyrklund, C.; Backman, J T.; Neuvonen, M.; Neuvonen, P J. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin. Pharmacol. Ther. 2003, 73 (6), 538–544. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Backman, J T.; Kyrklund, C.; Kivisto, K T.; Wang, J S.; Neuvonen, P J. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin. Pharmacol. Ther. 2000, 68 (2), 122–129. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Yu, D K. The contribution of P-glycoprotein to pharmacokinetic drug–drug interactions. J. Clin. Pharmacol. 1999, 39 (12), 1203–1211. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Tanigawara, Y. Role of P-glycoprotein in drug disposition. Ther. Drug Monit. 2000, 22 (1), 137–140. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Corsini, A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc. Drugs Ther. 2003, 17 (3), 265–285. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Carswell, C I.; Plosker, G L.; Jarvis, B. Rosuvastatin. Drugs 2002, 62 (14), 2075–2085, discussion 86–7. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Simonson, S G.; Raza, A.; Martin, P D.; Mitchell, P D.; Jarcho, J A.; Brown, C D.; Windass, A S.; Schneck, D W. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. 2004, 76 (2), 167–177. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Spence, J D.; Munoz, C E.; Hendricks, L.; Latchinian, L.; Khouri, H E. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am. J. Cardiol. 1995, 76 (2), 80A–83A. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Jacobson, T A.; Chin, M M.; Fromell, G J.; Jokubaitis, L A.; Amorosa, L F. Fluvastatin with and without niacin for hypercholesterolemia. Am. J. Cardiol. 1994, 74 (2), 149–154. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Smith, H T.; Jokubaitis, L A.; Troendle, A J.; Hwang, D S.; Robinson, W T. Pharmacokinetics of fluvastatin and specific drug interactions. Am. J. Hypertens. 1993, 6 (11 Pt 2), 375S–382S. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ichimaru, N.; Takahara, S.; Moriyama, T.; Kondo, M.; Nonomura, N.; Tanaka, T.; Wang, J D.; Imai, E.; Okuyama, A.; Kondo, Y. Pharmacokinetics and lipid-lowering effect of fluvastatin in hypercholesterolemic patients on maintenance hemodialysis. J. Int. Med. Res. 2004, 32 (1), 45–52. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Bruckert, E.; Lievre, M.; Giral, P.; Crepaldi, G.; Masana, L.; Vrolix, M.; Leitersdorf, E.; Dejager, S. Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. Am. J. Geriatr. Cardiol. 2003, 12 (4), 225–231. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Ballantyne, C M.; Pazzucconi, F.; Pinto, X.; Reckless, J P.; Stein, E.; McKenney, J.; Bortolini, M.; Chiang, Y T. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin. Ther. 2001, 23 (2), 177–192. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Quaschning, T.; Mainka, T.; Nauck, M.; Rump, L C.; Wanner, C.; Kramer-Guth, A. Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Inter., Suppl. 1999, 71: S235–S237. [CROSSREF], [CSA]
   Google Scholar
• Winkler, K.; Abletshauser, C.; Hoffmann, M M.; Friedrich, I.; Baumstark, M W.; Wieland, H.; Marz, W. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J. Clin. Endocrinol. Metab. 2002, 87 (12), 5485–5490., [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Corsini, A.; Pazzucconi, F.; Arnaboldi, L.; Pfister, P.; Fumagalli, R.; Paoletti, R.; Sirtori, C R. Direct effects of statins on the vascular wall. J. Cardiovasc. Pharmacol. 1998, 31 (5), 773–778. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Bellosta, S.; Bernini, F.; Ferri, N.; Quarato, P.; Canavesi, M.; Arnaboldi, L.; Fumagalli, R.; Paoletti, R.; Corsini, A. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998, 137 (Suppl), S101–S109. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Bellosta, S.; Ferri, N.; Arnaboldi, L.; Bernini, F.; Paoletti, R.; Corsini, A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 2000, 2: B72–B78.
   Google Scholar
• Kimura, M.; Kurose, I.; Russell, J.; Granger, D N. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler. Thromb. Vasc. Biol. 1997, 17 (8), 1521–1526. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ogata, Y.; Takahashi, M.; Takeuchi, K.; Ueno, S.; Mano, H.; Ookawara, S.; Kobayashi, E.; Ikeda, U.; Shimada, K. Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy. J. Cardiovasc. Pharmacol. 2002, 40 (6), 907–915. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ito, T.; Ikeda, U.; Shimpo, M.; Ohki, R.; Takahashi, M.; Yamamoto, K.; Shimada, K. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc. Drugs Ther. 2002, 16 (2), 121–126. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Corsini, A.; Pazzucconi, F.; Pfister, P.; Paoletti, R.; Sirtori, C R. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet 1996, 348 (9041), 1584. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mussoni, L.; Banfi, C.; Sironi, L.; Arpaia, M.; Tremoli, E. Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. Thromb. Haemost. 2000, 84 (1), 59–64. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sakaeda, T.; Takara, K.; Kakumoto, M.; Ohmoto, N.; Nakamura, T.; Iwaki, K.; Tanigawara, Y.; Okumura, K. Simvastatin and lovastatin, but not pravastatin, interact with MDR1. J. Pharm. Pharmacol. 2002, 54 (3), 419–423. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Rikitake, Y.; Kawashima, S.; Takeshita, S.; Yamashita, T.; Azumi, H.; Yasuhara, M.; Nishi, H.; Inoue, N.; Yokoyama, M. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001, 154 (1), 87–96. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Corsini, A. Fluvastatin: effects beyond cholesterol lowering. J. Cardiovasc. Pharmacol. Ther. 2000, 5 (3), 161–175. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Corsini, A. The use of statins in optimising reduction of cardiovascular risk: focus on fluvastatin. Int. J. Clin. Pract. 2004, 58 (5), 494–503. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Seliger, S L.; Weiss, N S.; Gillen, D L.; Kestenbaum, B.; Ball, A.; Sherrard, D J.; Stehman-Breen, C O. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002, 61 (1), 297–304. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tonelli, M.; Moye, L.; Sacks, F M.; Kiberd, B.; Curhan, G. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Annu. Intern. Med. 2003, 138 (2), 98–104.
   PubMedGoogle Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360 (9326), 7–22. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lintott, C J.; Scott, R S.; Bremer, J M.; Shand, B I. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. Am. J. Cardiol. 1995, 76 (2), 97A–101A. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Samuelsson, O.; Attman, P O.; Knight-Gibson, C.; Mulec, H.; Weiss, L.; Alaupovic, P. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. Am. J. Kidney Dis. 2002, 39 (1), 67–75. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Matzkies, F K.; Bahner, U.; Teschner, M.; Hohage, H.; Heidland, A.; Schaefer, R M. Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome. Am. J. Nephrol. 1999, 19 (4), 492–494. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Samuelsson, O.; Mulec, H.; Knight-Gibson, C.; Attman, P O.; Kron, B.; Larsson, R.; Weiss, L.; Wedel, H.; Alaupovic, P. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol. Dial. Transplant. 1997, 12: 1908–1915. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kasiske, B L.; Tortorice, K L.; Heim-Duthoy, K L.; Awni, W M.; Rao, K V. The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am. J. Kidney Dis. 1991, 17 (6), 700–707. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Holdaas, H.; Fellstrom, B.; Jardine, A.; Holme, I.; Nyberg, G.; Fauchald, P.; Gronhagen-Riska, C.; Madsen, S.; Neumayer, H H.; Cole, E.; Maes, B.; Ambuhl, P.; AG, O.; Hartmann, A.; DA, S.; Pedersen, T R. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003, 361 (9374), 2024–2031., [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kosch, M.; Barenbrock, M.; Suwelack, B.; Schaefer, R M.; Rahn, K H.; Hausberg, M. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. Am. J. Kidney Dis. 2003, 41 (5), 1088–1096. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Hausberg, M.; Kosch, M.; Stam, F.; Heidenreich, S.; Kisters, K.; Rahm, K H.; Barenbrock, M.. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. Kidney Int. 2001, 59 (4), 1473–1479. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Holdaas, H.; Jardine, A G.; Wheeler, D C.; Brekke, I B.; Conlon, P J.; Fellstrom, B.; Hammad, A.; Holme, I.; Isoniemi, H.; Moore, R.; Rowe, P A.; Sweny, P.; Talbot, D A.; Wadstrom, J.; Ostraat, O.. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int. 2001, 60 (5), 1990–1997. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Asberg, A.; Holdaas, H.; Jardine, A G.; Edvardsen, C.; Hartmann, A. Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clin. Transplant. 2003, 17 (4), 385–390. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Akiyama, T.; Ishii, T.; Imanishi, M.; Nishioka, T.; Matsuura, T.; Kurita, T. Efficacy and safety of treatment with low-dose fluvastatin in hypercholesterolemic renal transplant recipients. Transplant. Proc. 2001, 33 (3), 2115–2118. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Gomez, G.; Alvarez, M L.; Errasti, P.; Lavilla, F J.; Garcia, N.; Ballester, B.; Garcia, I.; Purroy, A.. Fluvastatin in the treatment of hypercholesterolemia in renal transplantation. Transplant. Proc. 1999, 31 (6), 2326–2327. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Holdaas, H.; Hartmann, A.; Stenstrom, J.; Dahl, K J.; Borge, M.; Pfister, P. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am. J. Cardiol. 1995, 76 (2), 102A–106A. [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Malyszko, J.; Malyszko, J S.; Mysliwiec, M. Fluvastatin therapy affects TAFI concentration in kindey transplant recipients. Transpl. Int. 2003, 16: 53–57. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Podder, H.; Gero, L.; Foldes, K.; Szabo, J.; Lazar, N.; Jaray, J. Treatment of metabolic disorders with fluvastatin after renal transplantation. Transplant. Proc. 1997, 29: 216–219. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Foldes, K.; Maklary, E.; Vargha, P.; , et al. Effect of diet and fluvastatin treatment on the serum lipid profile of kidney transplant diabetic recipients: a 1-year follow-up. Transpl. Int. 1998, 11 (Suppl 1), S65–S68. [PUBMED], [INFOTRIEVE]
   Google Scholar
• Riegger, G.; Abletshauser, C.; Ludwig, M.; Schwandt, P.; Widimsky, J.; Weidinger, G.; Weizel, D.. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999, 144 (1), 263–270. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Saia, F.; de Feyter, P.; Serruys, P W.; Lemos, P A.; Arampatzis, C A.; Hendrickx, G R.; Delarche, N.; Goedhart, D.; Lesaffre, E.; Branzi, A.. Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation. Am. J. Cardiol. 2004, 93 (1), 92–95. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Jardine, A G.; Holdaas, H.; Fellstrom, B.; Cole, E.; Nyberg, G.; Gronhagen-Riska, C.; Madsen, S.; Neumayer, H H.; Maes, B.; Ambuhl, P.; Olsson, A G.; Holme, I.; Fauchald, P.; Gimpelwicz, C.; Pedersen, T R. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am. J. Transplant. 2004, 4 (6), 988–995. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goldberg, R.; Roth, D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996, 62 (11), 1559–1564. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Yukawa, S.; Mune, M.; Yamada, Y.; Otani, H.; Kishino, M.; Tone, Y. Ongoing clinical trials of lipid reduction therapy in patients with renal disease. Kidney Inter., Suppl. 1999, 71: S141–S143. [CSA]
   PubMedGoogle Scholar
• Oda, H.; Keane, W F. Recent advances in statins and the kidney. Kidney Inter., Suppl. 1999, 71: S2–S5. [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Romano, M.; Mezzetti, A.; Marulli, C.; Ciabattoni, G.; Febo, F.; Di Ienno, S.; Roccaforte, S.; Vigneri, S.; Nubile, G.; Milani, M.; Davi, G.. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J. Investig. Med. 2000, 48 (3), 183–189. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Fischetti, F.; Carretta, R.; Borotto, G.; Durigutto, P.; Bulla, R.; Meroni, P L.; Tedesco, F.. Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. Clin. Exp. Immunol. 2004, 135 (2), 186–193. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Imaeda, A.; Tanigawa, T.; Aoki, T.; Kondo, Y.; Nakamura, N.; Yoshikawa, T. Antioxidative effects of fluvastatin and its metabolites against oxidative DNA damage in mammalian cultured cells. Free Radic. Res. 2001, 35 (6), 789–801. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Okada, M.; Yanagida, H.; Kuwajima, H.; Takemura, T. Antiproliferative effect of fluvastatin andthiazolidinedione in mesangial cells of diabetic rats. Pediatr. Nephrol. 2004, 19 (1), 26–32. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• van Haelst, P L.; van Doormaal, J J.; May, J F.; Gans, R O.; Crijns, H J.; Cohen Tervaert, J W. Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein. Eur. J. Intern. Med. 2001, 12 (6), 503–509. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Song, Y.; Li, C.; Cai, L. Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation. Exp. Mol. Pathol. 2004, 76 (1), 66–75. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Buemi, M.; Allegra, A.; Corica, F.; Aloisi, C.; Giacobbe, M.; Pettinato, G.; Corsonello, A.; Senatore, M.; Frisina, N.. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin. Pharmacol. Ther. 2000, 67 (4), 427–431. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Gheith, O A.; Sobh, M A.; Mohamed Kel, S.; El-Baz, M A.; El-Husseini, F.; Gazarin, S S.; Ahmed, H A.; Rasem, M W.; Amer, G M. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron 2002, 91 (4), 612–619. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Grundy, S M.; Cleeman, J I.; Merz, C N.; Brewer, H B. Jr.; Clark, L T.; Hunninghake, D B.; Pasternak, R C.; Smith, S C. Jr.; Stone, N J. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004, 110 (2), 227–239. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Martinez-Castelao, A.; Grinyo, J M.; Fiol, C.; Castineiras, M J.; Hurtado, I.; Gil-Vernet, S.; Seron, D.; Porta, I.; Minarro, A.; Villarroya, A.; Alsina, J.. Fluvastatin and low-density lipoprotein oxidation in hypercholesterolemic renal transplant patients. Kidney Inter., Suppl. 1999, 71: S231–S234. [CROSSREF]
   Google Scholar
• Martinez-Castelao, A.; Grinyo, J M.; Gil-Vernet, S.; Seron, D.; Castineiras, M J.; Ramos, R.; Alsina, J.. Lipid-lowering long-term effects of six different statins in hypercholesterolemic renal translplant patients under cyclosporine immunosuppression. Transplant. Proc. 2002, 34: 398–400. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hadjigavriel, M.; Kyriakides, G. Fluvastatin in renal transplantation. Transplant. Proc. 1997, 29 (7), 3050. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Li, P K.; Mak, T W.; Chan, T H.; Wang, A.; Lam, C W.; Lai, K N. Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia. Transplantation 1995, 60 (7), 652–656. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Locsey, L.; Asztalos, L.; Kincses, Z.; Balazs, G. Fluvastatin (Lescol) treatment of hyperlipidemia in patients with renal transplants. Int. Urol. Nephrol. 1997, 29 (1), 95–106. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Ghods, A J.; Milanian, I.; Arghani, H.; Ghadiri, G. The efficacy and safety of fluvastatin in hypercholesterolemia in renal transplant recipients. Transplant. Proc. 1995, 27 (5), 2579–2580. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Malyszko, J S.; Malyszko, J.; Mysliwiec, M. Serum lipids and hemostasis in kidney allograft recipients treated with fluvastatin (Lescol) for 3 months. Transplant. Proc. 2000, 32 (6), 1344–1346. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Turk, S.; Yildiz, A.; Tukek, T.; Akkaya, V.; Aras, U.; Turkmen, A.; Uras, A R.; Server, M S. The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study. Int. Urol. Nephrol. 2001, 32 (4), 713–716. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Austen, J L.; Shifrin, F A.; Bartucci, M R.; Knauss, T C.; Schulak, J A.; Hricik, D E. Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy. Ann. Pharmacother. 1996, 30 (12), 1386–1389. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar